{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036256","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2026-08-06T11:15:26+00:00","discovered_at":"2026-08-06T11:20:00.387184+00:00","generated_at":"2026-08-06T11:20:16.193205+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harrow acquires global rights to TYRVAYA nasal spray for dry eye disease from Viatris for up to $100M","bullets":["$30M cash at closing plus up to $70M in contingent milestone payments tied to TYRVAYA net sales.","TYRVAYA is first and only FDA-approved nasal spray for dry eye disease; approved in US, China, Taiwan.","Complements Harrow's VEVYE franchise with different mechanism (stimulates basal tear production vs anti-inflammatory).","Expected to close in H2 2026, subject to customary closing conditions.","Harrow expects to fund upfront cash payment from cash on hand."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036256","json":"https://secwatch.observer/filing/0001493152-26-036256.json","markdown":"https://secwatch.observer/filing/0001493152-26-036256.md","text":"https://secwatch.observer/filing/0001493152-26-036256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/0001493152-26-036256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315226036256/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:20:16.193205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}